Yi-Long Wu
吴一龙
MD
President, Guangdong Lung Cancer Institute广东省肺癌研究所所长
👥Biography 个人简介
Dr. Yi-Long Wu is a globally recognized pioneer in EGFR-mutated lung cancer. He led the landmark ADJUVANT trial, the first to demonstrate OS benefit of gefitinib adjuvant therapy in resected NSCLC, and co-pioneered the IPASS trial defining EGFR testing as standard practice across Asia.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
ADJUVANT Trial
Led the ADJUVANT/CTONG1104 trial, the first randomized study to show overall survival benefit of gefitinib over chemotherapy as adjuvant therapy in EGFR-mutated resected NSCLC.
EGFR Biomarker Research
Co-led IPASS trial analyses establishing EGFR mutation as the definitive predictive biomarker for TKI benefit, transforming lung cancer diagnosis globally.
Asia-Pacific Guidelines
Chaired multiple Asia-Pacific oncology guideline committees, harmonizing EGFR-targeted therapy protocols across diverse regional healthcare systems.
Representative Works 代表性著作
Gefitinib versus vinorelbine+cisplatin for resected non-small-cell lung cancer with EGFR mutation (ADJUVANT)
The Lancet Oncology (2018)
First trial to show significant DFS benefit of adjuvant gefitinib over chemotherapy in EGFR-mutated stage II-IIIA NSCLC, changing surgical oncology practice.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 6)
The Lancet Oncology (2013)
Demonstrated superior PFS with afatinib versus chemotherapy in Asian EGFR-mutated NSCLC patients, confirming second-generation TKI benefit.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 吴一龙 的研究动态
Follow Yi-Long Wu's research updates
留下邮箱，当我们发布与 Yi-Long Wu（Guangdong Provincial People's Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment